Drug Profile
Research programme: cyclin-dependent kinase 3 inhibitors - Senex Biotechnology
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Senex Biotechnology
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 04 Sep 2023 Preclinical development is ongoing in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 01 Jul 2016 Preclinical trials in Colorectal cancer in USA (unspecified route)